TWI344375B - Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative - Google Patents

Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Download PDF

Info

Publication number: TWI344375B
Authority: TW; Taiwan
Prior art keywords: dosage form; tablet; hydrochloride; ethyl; pioglitazone
Prior art date: 2005-03-30

Application number

TW095109953A

Other languages

English (en)

Chinese (zh)

Other versions

TW200718433A (en

Inventor

Unchalee Lodin

Jack Cardinal

Avinash Nangia

Kazuhrio Okochi

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-30

Filing date

2006-03-22

Publication date

2011-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI344375(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-22 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2007-05-16 Publication of TW200718433A publication Critical patent/TW200718433A/zh

2011-07-01 Application granted granted Critical

2011-07-01 Publication of TWI344375B publication Critical patent/TWI344375B/zh

Links

229940123208 Biguanide Drugs 0.000 title description 6
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title description 4
239000008194 pharmaceutical composition Substances 0.000 title description 4
150000001467 thiazolidinediones Chemical class 0.000 title 1
239000003826 tablet Substances 0.000 claims description 206
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 120
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical class CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 85
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims description 64
229960004329 metformin hydrochloride Drugs 0.000 claims description 64
239000002552 dosage form Substances 0.000 claims description 60
239000007937 lozenge Substances 0.000 claims description 59
229960005095 pioglitazone Drugs 0.000 claims description 59
239000003795 chemical substances by application Substances 0.000 claims description 49
-1 diterpenoid hydrochloride Chemical class 0.000 claims description 49
239000013543 active substance Substances 0.000 claims description 42
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
238000013268 sustained release Methods 0.000 claims description 28
239000012730 sustained-release form Substances 0.000 claims description 28
238000007789 sealing Methods 0.000 claims description 27
NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims description 25
GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims description 25
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 25
229960002827 pioglitazone hydrochloride Drugs 0.000 claims description 25
239000003623 enhancer Substances 0.000 claims description 24
229930004069 diterpene Natural products 0.000 claims description 22
239000000872 buffer Substances 0.000 claims description 19
239000011230 binding agent Substances 0.000 claims description 16
238000004128 high performance liquid chromatography Methods 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
238000012360 testing method Methods 0.000 claims description 15
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 14
229960003105 metformin Drugs 0.000 claims description 14
230000004907 flux Effects 0.000 claims description 13
239000012535 impurity Substances 0.000 claims description 13
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 12
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 12
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 12
229920000642 polymer Polymers 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
238000003860 storage Methods 0.000 claims description 11
238000010521 absorption reaction Methods 0.000 claims description 10
230000003204 osmotic effect Effects 0.000 claims description 10
239000004014 plasticizer Substances 0.000 claims description 9
150000002576 ketones Chemical class 0.000 claims description 6
239000000314 lubricant Substances 0.000 claims description 6
235000012054 meals Nutrition 0.000 claims description 6
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
239000000853 adhesive Substances 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000004076 pyridyl group Chemical group 0.000 claims description 4
239000003232 water-soluble binding agent Substances 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
230000001070 adhesive effect Effects 0.000 claims description 3
230000008961 swelling Effects 0.000 claims description 3
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
230000000694 effects Effects 0.000 claims description 2
239000007891 compressed tablet Substances 0.000 claims 5
239000007864 aqueous solution Substances 0.000 claims 2
239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
229960003009 clopidogrel Drugs 0.000 claims 1
125000005594 diketone group Chemical group 0.000 claims 1
125000005567 fluorenylene group Chemical group 0.000 claims 1
239000008240 homogeneous mixture Substances 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 claims 1
230000036470 plasma concentration Effects 0.000 claims 1
125000003396 thiol group Chemical class [H]S* 0.000 claims 1
238000000576 coating method Methods 0.000 description 136
239000011248 coating agent Substances 0.000 description 112
239000007921 spray Substances 0.000 description 63
239000000203 mixture Substances 0.000 description 59
239000000243 solution Substances 0.000 description 53
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
239000006185 dispersion Substances 0.000 description 40
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
239000000725 suspension Substances 0.000 description 32
238000013270 controlled release Methods 0.000 description 31
150000001875 compounds Chemical class 0.000 description 29
238000002156 mixing Methods 0.000 description 26
239000000463 material Substances 0.000 description 24
238000000889 atomisation Methods 0.000 description 23
229920002301 cellulose acetate Polymers 0.000 description 23
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 20
239000003472 antidiabetic agent Substances 0.000 description 20
230000003068 static effect Effects 0.000 description 20
229920003116 HPC-SSL Polymers 0.000 description 19
238000009500 colour coating Methods 0.000 description 19
239000000843 powder Substances 0.000 description 19
229960000583 acetic acid Drugs 0.000 description 16
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
239000004204 candelilla wax Substances 0.000 description 15
229940073532 candelilla wax Drugs 0.000 description 15
235000013868 candelilla wax Nutrition 0.000 description 15
239000012362 glacial acetic acid Substances 0.000 description 15
IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 15
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 14
239000005695 Ammonium acetate Substances 0.000 description 14
229940043376 ammonium acetate Drugs 0.000 description 14
235000019257 ammonium acetate Nutrition 0.000 description 14
239000000306 component Substances 0.000 description 14
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
238000013022 venting Methods 0.000 description 14
239000012530 fluid Substances 0.000 description 13
238000000034 method Methods 0.000 description 13
239000004353 Polyethylene glycol 8000 Substances 0.000 description 11
239000004480 active ingredient Substances 0.000 description 11
239000003814 drug Substances 0.000 description 11
229940085678 polyethylene glycol 8000 Drugs 0.000 description 11
235000019446 polyethylene glycol 8000 Nutrition 0.000 description 11
239000011734 sodium Substances 0.000 description 11
229910052708 sodium Inorganic materials 0.000 description 11
239000004698 Polyethylene Substances 0.000 description 10
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
229940079593 drug Drugs 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000001087 glyceryl triacetate Substances 0.000 description 10
235000013773 glyceryl triacetate Nutrition 0.000 description 10
239000002245 particle Substances 0.000 description 10
229920000573 polyethylene Polymers 0.000 description 10
235000019333 sodium laurylsulphate Nutrition 0.000 description 10
239000004408 titanium dioxide Substances 0.000 description 10
229960002622 triacetin Drugs 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
239000000047 product Substances 0.000 description 9
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
229920002678 cellulose Polymers 0.000 description 8
239000001913 cellulose Substances 0.000 description 8
239000008187 granular material Substances 0.000 description 8
229960001375 lactose Drugs 0.000 description 8
239000008101 lactose Substances 0.000 description 8
229960001021 lactose monohydrate Drugs 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
239000008280 blood Substances 0.000 description 7
239000007853 buffer solution Substances 0.000 description 7
239000007888 film coating Substances 0.000 description 7
238000009501 film coating Methods 0.000 description 7
238000005498 polishing Methods 0.000 description 7
229940068918 polyethylene glycol 400 Drugs 0.000 description 7
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
229920000053 polysorbate 80 Polymers 0.000 description 7
238000001694 spray drying Methods 0.000 description 7
229910001220 stainless steel Inorganic materials 0.000 description 7
239000010935 stainless steel Substances 0.000 description 7
239000004094 surface-active agent Substances 0.000 description 7
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000002058 anti-hyperglycaemic effect Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000005352 clarification Methods 0.000 description 6
239000002274 desiccant Substances 0.000 description 6
238000001035 drying Methods 0.000 description 6
229920001903 high density polyethylene Polymers 0.000 description 6
239000004700 high-density polyethylene Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000002195 soluble material Substances 0.000 description 6
239000011877 solvent mixture Substances 0.000 description 6
239000001993 wax Substances 0.000 description 6
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 5
206010036790 Productive cough Diseases 0.000 description 5
230000001133 acceleration Effects 0.000 description 5
238000002309 gasification Methods 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
229920001983 poloxamer Polymers 0.000 description 5
229920006316 polyvinylpyrrolidine Polymers 0.000 description 5
210000003802 sputum Anatomy 0.000 description 5
208000024794 sputum Diseases 0.000 description 5
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
150000004141 diterpene derivatives Chemical class 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000008213 purified water Substances 0.000 description 4
238000005507 spraying Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
239000000052 vinegar Substances 0.000 description 4
235000021419 vinegar Nutrition 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
239000003125 aqueous solvent Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229910052797 bismuth Inorganic materials 0.000 description 3
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 3
239000007767 bonding agent Substances 0.000 description 3
239000008358 core component Substances 0.000 description 3
210000003298 dental enamel Anatomy 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000005553 drilling Methods 0.000 description 3
239000000565 sealant Substances 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
239000002689 soil Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
229910000406 trisodium phosphate Inorganic materials 0.000 description 3
235000019801 trisodium phosphate Nutrition 0.000 description 3
229920001747 Cellulose diacetate Polymers 0.000 description 2
229920002284 Cellulose triacetate Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
241001553290 Euphorbia antisyphilitica Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000007530 Neurofibromin 1 Human genes 0.000 description 2
108010085793 Neurofibromin 1 Proteins 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 2
229940125708 antidiabetic agent Drugs 0.000 description 2
235000013339 cereals Nutrition 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
BEQZMQXCOWIHRY-UHFFFAOYSA-H dibismuth;trisulfate Chemical compound [Bi+3].[Bi+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BEQZMQXCOWIHRY-UHFFFAOYSA-H 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000000975 dye Substances 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000012046 mixed solvent Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
150000002917 oxazolidines Chemical class 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
239000012466 permeate Substances 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229960000502 poloxamer Drugs 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000001069 triethyl citrate Substances 0.000 description 2
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
235000013769 triethyl citrate Nutrition 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
238000009941 weaving Methods 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
VFQADAFGYKTPSH-UHFFFAOYSA-N 1,1-dimethylhydrazine;hydron;chloride Chemical compound Cl.CN(C)N VFQADAFGYKTPSH-UHFFFAOYSA-N 0.000 description 1
LFRHMTZYADABJZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)butan-2-amine;hydron;chloride Chemical compound Cl.CCC(N)CC1=CC=C2OCOC2=C1 LFRHMTZYADABJZ-UHFFFAOYSA-N 0.000 description 1
FKPUYTAEIPNGRM-UHFFFAOYSA-N 1-(diaminomethylidene)guanidine;hydron;chloride Chemical compound [Cl-].N\C([NH3+])=N/C(N)=N FKPUYTAEIPNGRM-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
CGWBIHLHAGNJCX-UHFFFAOYSA-N 2-butylguanidine Chemical class CCCCNC(N)=N CGWBIHLHAGNJCX-UHFFFAOYSA-N 0.000 description 1
FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
WMRXHQRDCIXTCD-UHFFFAOYSA-N 3-hydrazinylpropan-1-ol Chemical compound NNCCCO WMRXHQRDCIXTCD-UHFFFAOYSA-N 0.000 description 1
JKYYOLNHZUIMKT-UHFFFAOYSA-N 3a,4,5,6-tetrahydro-3h-indene-1,2-dione Chemical compound C1CCC=C2C(=O)C(=O)CC21 JKYYOLNHZUIMKT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
WWXUGNUFCNYMFK-UHFFFAOYSA-N Acetyl citrate Chemical compound CC(=O)OC(=O)CC(O)(C(O)=O)CC(O)=O WWXUGNUFCNYMFK-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920008347 Cellulose acetate propionate Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
QPUFIKZJKNNFDW-UHFFFAOYSA-N Cl.Cl.Cl.[Bi] Chemical compound Cl.Cl.Cl.[Bi] QPUFIKZJKNNFDW-UHFFFAOYSA-N 0.000 description 1
WIUZQNJQVLSLOK-UHFFFAOYSA-N Cl.Cl.[Bi] Chemical compound Cl.Cl.[Bi] WIUZQNJQVLSLOK-UHFFFAOYSA-N 0.000 description 1
MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920003115 HPC-SL Polymers 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GIKDYMRZQQJQFB-UHFFFAOYSA-N Methylhydrazine hydrochloride Chemical compound Cl.CNN GIKDYMRZQQJQFB-UHFFFAOYSA-N 0.000 description 1
HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 1
235000012851 Myrica pensylvanica Nutrition 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
244000019180 Parmentiera cereifera Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
244000062793 Sorghum vulgare Species 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
ZZAGLMPBQOKGGT-UHFFFAOYSA-N [4-[4-(4-prop-2-enoyloxybutoxy)benzoyl]oxyphenyl] 4-(4-prop-2-enoyloxybutoxy)benzoate Chemical compound C1=CC(OCCCCOC(=O)C=C)=CC=C1C(=O)OC(C=C1)=CC=C1OC(=O)C1=CC=C(OCCCCOC(=O)C=C)C=C1 ZZAGLMPBQOKGGT-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940053194 antiepileptics oxazolidine derivative Drugs 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
238000003287 bathing Methods 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
ANERHPOLUMFRDC-UHFFFAOYSA-K bismuth citrate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ANERHPOLUMFRDC-UHFFFAOYSA-K 0.000 description 1
238000007664 blowing Methods 0.000 description 1
229960004111 buformin Drugs 0.000 description 1
XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
235000021438 curry Nutrition 0.000 description 1
DCZFGQYXRKMVFG-UHFFFAOYSA-N cyclohexane-1,4-dione Chemical class O=C1CCC(=O)CC1 DCZFGQYXRKMVFG-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229960002097 dibutylsuccinate Drugs 0.000 description 1
IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 1
WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000002320 enamel (paints) Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
239000003292 glue Substances 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
239000008169 grapeseed oil Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
238000003475 lamination Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
UDKXQFAVKLBFDG-UHFFFAOYSA-L magnesium;sodium;dodecyl sulfate;octadecanoate Chemical compound [Na+].[Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC([O-])=O UDKXQFAVKLBFDG-UHFFFAOYSA-L 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012907 medicinal substance Substances 0.000 description 1
229940103788 metformin hydrochloride 1000 mg Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
235000019713 millet Nutrition 0.000 description 1
239000003595 mist Substances 0.000 description 1
AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000007639 printing Methods 0.000 description 1
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
239000012744 reinforcing agent Substances 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000013517 stratification Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
BGKZULDOBMANRY-UHFFFAOYSA-N sulfanyl prop-2-enoate Chemical compound SOC(=O)C=C BGKZULDOBMANRY-UHFFFAOYSA-N 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1
235000020985 whole grains Nutrition 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

TW095109953A 2005-03-30 2006-03-22 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative TWI344375B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11/093,742 US9060941B2 (en)	2002-09-20	2005-03-30	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Publications (2)

Publication Number	Publication Date
TW200718433A TW200718433A (en)	2007-05-16
TWI344375B true TWI344375B (en)	2011-07-01

Family

ID=37073782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095109953A TWI344375B (en)	2005-03-30	2006-03-22	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Country Status (24)

Country	Link
US (1)	US9060941B2 (no)
EP (1)	EP1863445B1 (no)
JP (2)	JP5827781B2 (no)
KR (1)	KR101401412B1 (no)
CN (1)	CN101222912B (no)
AR (1)	AR054238A1 (no)
AU (1)	AU2006232993B2 (no)
BR (1)	BRPI0609550A2 (no)
CA (1)	CA2601501C (no)
CR (1)	CR9355A (no)
EA (1)	EA015244B1 (no)
ES (1)	ES2573321T3 (no)
GE (1)	GEP20104936B (no)
IL (1)	IL186308A (no)
MA (1)	MA29675B1 (no)
MX (1)	MX2007011824A (no)
NO (1)	NO20075427L (no)
NZ (1)	NZ561124A (no)
PE (1)	PE20061389A1 (no)
SG (1)	SG160415A1 (no)
TW (1)	TWI344375B (no)
UA (1)	UA91852C2 (no)
WO (1)	WO2006107528A1 (no)
ZA (1)	ZA200707137B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040102486A1 (en) *	1998-11-12	2004-05-27	Smithkline Beecham Corporation	Novel method of treatment
US20030153607A1 (en) *	1998-11-12	2003-08-14	Smithkline Beecham P.L.C.	Novel composition and use
AU2002356419A1 (en)	2002-06-17	2003-12-31	Themis Laboratories Private Limited	Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7785627B2 (en) *	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7588779B2 (en) *	2004-05-28	2009-09-15	Andrx Labs, Llc	Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
US20080026054A1 (en) *	2007-04-27	2008-01-31	Nectid Inc.	Novel anelgesic combination
US20080031950A1 (en) *	2007-04-27	2008-02-07	Nectid Inc.	Novel anelgesic combination
CN102036656A (zh) *	2008-03-21	2011-04-27	米兰制药有限公司	含有蜡的缓释制剂
DE102008059206A1 (de) *	2008-11-27	2010-06-10	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US20120093878A1 (en) *	2010-07-30	2012-04-19	Ranbaxy Laboratories Limited	Pharmaceutical compositions containing a biguanide and a thiazolidinedione
US20130251795A1 (en) *	2010-07-30	2013-09-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
CN101912375A (zh) *	2010-08-26	2010-12-15	冯岩	一种二甲双胍控释片
CN102727459A (zh) *	2011-04-15	2012-10-17	江苏豪森医药集团有限公司	一种具有第一和第二活性药物的制剂
BR112014008744A2 (pt)	2011-10-21	2017-04-18	Takeda Pharmaceuticals Co	preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
JPWO2014171542A1 (ja) *	2013-04-19	2017-02-23	武田薬品工業株式会社	放出制御製剤
EP3025707A1 (en) *	2014-11-27	2016-06-01	Arven Ilac Sanayi Ve Ticaret A.S.	A multilayer tablet comprising metformin and pioglitazone
JP2021533109A (ja) *	2018-08-02	2021-12-02	オスピタルサンジュアンダデウ	多嚢胞性卵巣症候群の治療に有用な医薬品有効成分の三重組合せの即時放出製剤
GB202006849D0 (en)	2020-05-08	2020-06-24	Kancera Ab	New use

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3174901A (en)	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3621097A (en)	1970-03-30	1971-11-16	Jan Marcel Didier Aron Samuel	Method and compositions for treatment of mental illness
US3960949A (en)	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4080472A (en)	1974-03-22	1978-03-21	Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S.	Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US4034758A (en)	1975-09-08	1977-07-12	Alza Corporation	Osmotic therapeutic system for administering medicament
US4077407A (en)	1975-11-24	1978-03-07	Alza Corporation	Osmotic devices having composite walls
US4058122A (en)	1976-02-02	1977-11-15	Alza Corporation	Osmotic system with laminated wall formed of different materials
US4166800A (en)	1977-08-25	1979-09-04	Sandoz, Inc.	Processes for preparation of microspheres
US4220648A (en)	1979-01-22	1980-09-02	The Upjohn Company	Antidiabetic 1,2-dihydro-2-oxo-6-neopentyl-nicotinic acids
US4389330A (en)	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
US4783337A (en)	1983-05-11	1988-11-08	Alza Corporation	Osmotic system comprising plurality of members for dispensing drug
US4968507A (en)	1984-06-20	1990-11-06	Merck & Co., Inc.	Controlled porosity osmotic pump
CA1266827A (en)	1984-06-20	1990-03-20	Merck & Co., Inc.	Controlled porosity osmotic pump
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
IT1188212B (it)	1985-12-20	1988-01-07	Paolo Colombo	Sistema per il rilascio a velocita' controllata di sostanze attive
GB8618811D0 (en)	1986-08-01	1986-09-10	Approved Prescription Services	Sustained release ibuprofen formulation
CH668187A5 (de)	1986-08-07	1988-12-15	Ciba Geigy Ag	Therapeutisches system mit systemischer wirkung.
FR2611500B1 (fr)	1987-03-06	1990-05-04	Lipha	Emploi de derives du biguanide dans la preparation de medicaments
US4891223A (en)	1987-09-03	1990-01-02	Air Products And Chemicals, Inc.	Controlled release delivery coating formulation for bioactive substances
GB8724763D0 (en)	1987-10-22	1987-11-25	Aps Research Ltd	Sustained-release formulations
US4857337A (en)	1988-05-24	1989-08-15	American Home Products Corp. (Del)	Enteric coated aspirin tablets
US5612059A (en)	1988-08-30	1997-03-18	Pfizer Inc.	Use of asymmetric membranes in delivery devices
JP2885858B2 (ja)	1989-01-31	1999-04-26	イー・ペー・アー・インテルナチオナーレ・ファルマ・アゲンチュル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	有効物質の制御放出システムおよびその製造方法
DD295760A5 (de)	1989-01-31	1991-11-14	Martin-Luther-Universitaet Halle Wittenberg,De	Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5356913A (en)	1990-02-09	1994-10-18	The Upjohn Company	Use of insulin sensitizing agents to treat hypertension
WO1993003724A1 (en)	1991-08-26	1993-03-04	The Upjohn Company	Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5200194A (en)	1991-12-18	1993-04-06	Alza Corporation	Oral osmotic device
US5294770A (en)	1992-01-14	1994-03-15	Alza Corporation	Laser tablet treatment system with dual access to tablet
US5376771A (en)	1992-07-07	1994-12-27	Merck & Co., Inc.	High speed process for preparing orifices in pharmaceutical dosage forms
WO1994008709A1 (fr) *	1992-10-09	1994-04-28	Kanegafuchi Kagaku Kogyo Kabushiki Kaisha	Procede de production de granules fins
DE69425453T2 (de)	1993-04-23	2001-04-12	Novartis Ag, Basel	Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5478852C1 (en)	1993-09-15	2001-03-13	Sankyo Co	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de)	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5917052A (en)	1994-09-28	1999-06-29	Shaman Pharmaceuticals, Inc.	Hypoglycemic agent from cryptolepis
AUPM897594A0 (en)	1994-10-25	1994-11-17	Daratech Pty Ltd	Controlled release container
US5858398A (en)	1994-11-03	1999-01-12	Isomed Inc.	Microparticular pharmaceutical compositions
US5658474A (en)	1994-12-16	1997-08-19	Alza Corporation	Method and apparatus for forming dispenser delivery ports
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en)	1995-07-03	1999-07-14	Sankyo Co	Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US5972389A (en)	1996-09-19	1999-10-26	Depomed, Inc.	Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5859037A (en)	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes
US6011049A (en)	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
US6291495B1 (en)	1997-02-24	2001-09-18	Robert B. Rieveley	Method and composition for the treatment of diabetes
AU729529B2 (en)	1997-06-06	2001-02-01	Depomed, Inc.	Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6056977A (en)	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
WO1999029314A1 (en)	1997-12-08	1999-06-17	Bristol-Myers Squibb Company	Novel salts of metformin and method
US5948440A (en) *	1997-12-17	1999-09-07	Ranbaxy Laboratories Limited	Modified release matrix formulation of cefaclor and cephalexin
ID26082A (id)	1998-03-19	2000-11-23	Briston Myers Squib Company	Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya
US6099859A (en)	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
CA2330485C (en)	1998-04-29	2008-07-08	Sumitomo Pharmaceuticals Co., Ltd.	Oral formulation comprising biguanide and an organic acid
US6191162B1 (en)	1998-05-28	2001-02-20	Medical Research Institute	Method of reducing serum glucose levels
AR019727A1 (es)	1998-06-30	2002-03-13	Takeda Chemical Industries Ltd	Composicion farmaceutica
US6099862A (en)	1998-08-31	2000-08-08	Andrx Corporation	Oral dosage form for the controlled release of a biguanide and sulfonylurea
CZ20011629A3 (cs)	1998-11-12	2001-12-12	Smithkline Beecham Plc	Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US20040081697A1 (en)	1998-11-12	2004-04-29	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US7374779B2 (en)	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en)	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2371836C (en)	1999-05-27	2006-01-31	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
AU1403501A (en)	1999-11-16	2001-05-30	Smithkline Beecham Plc	Novel composition and use
MY125516A (en)	1999-11-16	2006-08-30	Smithkline Beecham Plc	Novel composition based on thiazolidinedione and metformin and use
IL150239A0 (en)	1999-12-16	2002-12-01	Alza Corp	Dosage forms having a barrier layer to laser ablation
JP2003518487A (ja)	1999-12-23	2003-06-10	ファイザー・プロダクツ・インク	ヒドロゲル駆動型積層薬物製剤
BR0007360A (pt)	1999-12-23	2001-08-14	Johnson & Johnson	Composição de liberação controlada
AR026148A1 (es)	2000-01-21	2003-01-29	Osmotica Argentina S A	Dispositivo osmotico con pasaje preformado que aumenta de tamano
SE0001151D0 (sv)	2000-03-31	2000-03-31	Amarin Dev Ab	Method for producing a controlled-release composition
US6524621B2 (en)	2000-05-01	2003-02-25	Aeropharm Technology Inc.	Core formulation
US6451342B2 (en)	2000-05-01	2002-09-17	Aeropharm Technology Incorporated	Core formulation comprised of troglitazone and a biguanide
US6780432B1 (en)	2000-05-01	2004-08-24	Aeropharm Technology, Inc.	Core formulation
US6403121B1 (en)	2000-05-01	2002-06-11	Aeropharm Technology Incorporated	Core formulation
US6296874B1 (en)	2000-05-01	2001-10-02	Aeropharm Technology Incorporated	Core formulation comprising troglitazone and abiguanide
DE10025946A1 (de)	2000-05-26	2001-11-29	Gruenenthal Gmbh	Wirkstoffkombination
US20030086972A1 (en)	2000-08-09	2003-05-08	Appel Leah E.	Hydrogel-driven drug dosage form
JP2004510716A (ja)	2000-10-02	2004-04-08	ユーエスヴイ　リミテッド	メトフォルミン含有持続性放出薬理組成物とその製造方法
US6790459B1 (en)	2000-11-03	2004-09-14	Andrx Labs, Llc	Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en)	2000-11-03	2005-03-15	Andrx Labs, Llc	Controlled release metformin compositions
US20060034922A1 (en)	2000-11-03	2006-02-16	Andrx Labs, Llc	Controlled release metformin compositions
JPWO2002060448A1 (ja)	2001-01-30	2004-05-27	帝人株式会社	医薬組成物
JP4848558B2 (ja)	2001-05-08	2011-12-28	トーアエイヨー株式会社	塩酸メトホルミン含有速放性錠剤
US6838093B2 (en) *	2001-06-01	2005-01-04	Shire Laboratories, Inc.	System for osmotic delivery of pharmaceutically active agents
WO2003004009A1 (en)	2001-07-02	2003-01-16	Geneva Pharmaceuticals, Inc.	Pharmaceutical composition
US6703045B2 (en)	2001-08-21	2004-03-09	Council Of Scientific & Industrial Research	Composition and method for maintaining blood glucose level
US20030118649A1 (en)	2001-10-04	2003-06-26	Jinming Gao	Drug delivery devices and methods
US20030091630A1 (en)	2001-10-25	2003-05-15	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030185882A1 (en)	2001-11-06	2003-10-02	Vergez Juan A.	Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) *	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
ITFI20010230A1 (it)	2001-11-29	2003-05-29	Menarini Int Operations Lu Sa	Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20030118647A1 (en)	2001-12-04	2003-06-26	Pawan Seth	Extended release tablet of metformin
US20030224046A1 (en)	2002-06-03	2003-12-04	Vinay Rao	Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
AU2002356419A1 (en)	2002-06-17	2003-12-31	Themis Laboratories Private Limited	Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
AU2003281181A1 (en)	2002-07-11	2004-02-02	Takeda Pharmaceutical Company Limited	Process for producing coated preparation
US7959946B2 (en)	2002-09-20	2011-06-14	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) *	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP2604266A1 (en)	2002-09-20	2013-06-19	Andrx Labs Llc	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
IN192749B (no)	2002-11-15	2004-05-15	Ranbaxy Lab Ltd
NZ541749A (en)	2003-01-29	2009-06-26	Takeda Pharmaceutical	Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
EP1696897B1 (en)	2003-12-19	2011-07-06	Omega Bio-Pharma (I.P.3) Limited	Compositions for treating diabetes
BRPI0510593A (pt)	2004-05-03	2007-11-20	Univ Duke	composições para afetar a perda de peso
CN1327840C (zh)	2004-06-08	2007-07-25	天津药物研究院	一种药物组合物及其在制备用于治疗糖尿病中的应用

2005
- 2005-03-30 US US11/093,742 patent/US9060941B2/en not_active Expired - Lifetime
2006
- 2006-03-13 BR BRPI0609550-0A patent/BRPI0609550A2/pt not_active IP Right Cessation
- 2006-03-13 CA CA2601501A patent/CA2601501C/en not_active Expired - Fee Related
- 2006-03-13 JP JP2008504090A patent/JP5827781B2/ja not_active Expired - Fee Related
- 2006-03-13 MX MX2007011824A patent/MX2007011824A/es active IP Right Grant
- 2006-03-13 WO PCT/US2006/009082 patent/WO2006107528A1/en not_active Ceased
- 2006-03-13 EP EP06738170.7A patent/EP1863445B1/en active Active
- 2006-03-13 EA EA200702116A patent/EA015244B1/ru not_active IP Right Cessation
- 2006-03-13 KR KR1020077021377A patent/KR101401412B1/ko not_active Expired - Fee Related
- 2006-03-13 ES ES06738170.7T patent/ES2573321T3/es active Active
- 2006-03-13 UA UAA200712007A patent/UA91852C2/ru unknown
- 2006-03-13 AU AU2006232993A patent/AU2006232993B2/en not_active Ceased
- 2006-03-13 GE GEAP200610344A patent/GEP20104936B/en unknown
- 2006-03-13 NZ NZ561124A patent/NZ561124A/en not_active IP Right Cessation
- 2006-03-13 CN CN2006800097636A patent/CN101222912B/zh not_active Expired - Fee Related
- 2006-03-13 SG SG201001858-8A patent/SG160415A1/en unknown
- 2006-03-15 AR AR20060100990A patent/AR054238A1/es unknown
- 2006-03-22 TW TW095109953A patent/TWI344375B/zh not_active IP Right Cessation
- 2006-03-30 PE PE2006000354A patent/PE20061389A1/es not_active Application Discontinuation
2007
- 2007-08-23 ZA ZA2007/07137A patent/ZA200707137B/en unknown
- 2007-08-29 CR CR9355A patent/CR9355A/es unknown
- 2007-09-25 IL IL186308A patent/IL186308A/en not_active IP Right Cessation
- 2007-10-11 MA MA30295A patent/MA29675B1/fr unknown
- 2007-10-25 NO NO20075427A patent/NO20075427L/no not_active Application Discontinuation
2013
- 2013-06-19 JP JP2013129075A patent/JP2013209426A/ja active Pending

Also Published As

Publication number	Publication date
HK1114337A1 (en)	2008-10-31
JP2013209426A (ja)	2013-10-10
CR9355A (es)	2008-01-21
EP1863445B1 (en)	2016-05-11
CA2601501A1 (en)	2006-10-12
IL186308A0 (en)	2011-08-01
ZA200707137B (en)	2014-07-30
KR101401412B1 (ko)	2014-06-11
MX2007011824A (es)	2008-02-12
US20050226928A1 (en)	2005-10-13
NO20075427L (no)	2007-10-25
CN101222912B (zh)	2012-10-03
AU2006232993A1 (en)	2006-10-12
EA200702116A1 (ru)	2008-02-28
WO2006107528A1 (en)	2006-10-12
US9060941B2 (en)	2015-06-23
TW200718433A (en)	2007-05-16
BRPI0609550A2 (pt)	2010-04-13
NZ561124A (en)	2010-12-24
EP1863445A1 (en)	2007-12-12
MA29675B1 (fr)	2008-08-01
AR054238A1 (es)	2007-06-13
CN101222912A (zh)	2008-07-16
UA91852C2 (ru)	2010-09-10
IL186308A (en)	2014-05-28
KR20080005359A (ko)	2008-01-11
CA2601501C (en)	2013-04-09
ES2573321T3 (es)	2016-06-07
EA015244B1 (ru)	2011-06-30
PE20061389A1 (es)	2007-01-21
JP2008534589A (ja)	2008-08-28
SG160415A1 (en)	2010-04-29
EP1863445A4 (en)	2012-08-01
GEP20104936B (en)	2010-03-25
AU2006232993B2 (en)	2012-01-19
JP5827781B2 (ja)	2015-12-02

Publication	Publication Date	Title
TWI344375B (en)	2011-07-01	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP6054909B2 (ja)	2016-12-27	ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤
TWI354569B (en)	2011-12-21	Coated tablet formulation and method
CN101094657B (zh)	2012-01-04	用于糖尿病药物的口服给药的控释复合制剂及其制备方法
CN100544717C (zh)	2009-09-30	含有双胍和噻唑烷二酮衍生物的药物剂型
US8668931B2 (en)	2014-03-11	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en)	2011-12-27	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
TWI361070B (en)	2012-04-01	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MXPA06002692A (en)	2006-12-13	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
HK1114337B (en)	2013-01-25	Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Legal Events

Date	Code	Title	Description
2016-04-01	MM4A	Annulment or lapse of patent due to non-payment of fees